Showing 1 - 2 results of 2 for search 'Ruixuan Luo', query time: 0.01s Refine Results
  1. 1
    Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyResearch in context

    Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyResearch in context by Panpan Zhang, Kai Chen, Jianwei Yang, Lijie Song, Fei Zheng, Ruixuan Luo, Yebo He, Feng Li, Di Yang, Nan Cao, Xiaolu Tao, Lin Shen, Ming Lu

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

    Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial by Michael Lee, Jing Chen, Li Yao, Yu Chen, Yu Jiang, Feng Li, Xiubao Ren, Jun Guo, Bixia Tang, Chuanliang Cui, Gang Huang, Shuai Zhao, Zhihong Chi, Meng Qi, Xiaolu Tao, Quanli Gao, Xiaoshi Zhang, Meiyu Fang, Fei Zheng, Rongqing Li, Meijuan Gao, Ruixuan Luo, Rong Duan

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: